glp-1 medication lifestyle changes gen z Nutritional priorities to support therapy for obesity: a joint Advisory from the American College of Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society What's behind Gen Z's skepticism

Growing Use Cases: Recent clinical trials have shown that GLP-1RAs can also support reducing cardiovascular risk and heart failure-related symptoms and slow down the progression of kidney diseases

By Geography, market is segmented by Brazil, Mexico, Argentina, Rest of Latin America

Who It's For (Based on Trial Inclusion Criteria) BMI 30 (obesity) OR BMI 27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, high cholesterol, sleep apnea) Adults ages 1875 (some trials include narrower age ranges) People who have tried lifestyle interventions (diet and exercise) without sufficient weight loss Those with type 2 diabetes seeking both glucose control and weight loss People with obesity-related conditions that would improve with major weight reduction Who Should Avoid Retatrutide Based on trial exclusion criteria and the drug's mechanism, retatrutide is likely not appropriate for: Pregnancy or breastfeeding: Not studied in these populations

Go search for "GLP-1 supplements" on Amazon right now

Scrocchi et al., 1996), this mechanism propelled the development of GLP-1 receptor agonists (GLP-1RAs), initially approved for diabetes (2005) and later for obesity (2014) (Jastreboff and Kushner, 2023)

I have been on a weight loss journey since gaining 215 lbs in 2023. I lost 30 lbs before trying Ultimate Weight Control, but got stuck